Home
About Lectranal®
Research
Product supply
About us
FAQ
News
Events
LECTRANAL® MARKETS
Contact us
EFFICACY AND SAFETY OF LECTRANAL® IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS SYMPTOMS
Pages 2 of 3
Improvement in SARS (Seasonal allergic rhinitis symptoms) and Mini RQLQ (Rhinoconjunctivitis quality of life questionnaire)
After 3 weeks of treatment there was a tendency towards statistically significant change in the SARS score.
Reduction of allergy symptoms on the SARS test after 3 weeks of treatment (p=0.118)
Reduction of allergy symptoms on the SARS test after 3 weeks of treatment (p=0.118)

During the ragweed season a statistically significant reduction in the symptoms was measured on both the SARS and Mini RQLQ tests.
Reduction of allergy symptoms on the SARS test after 3 weeks of treatment during ragweed season compared to the placebo (p=0.038)
Reduction of allergy symptoms on the SARS test after 3 weeks of treatment during ragweed season compared to the placebo (p=0.038)
Reduction of allergy symptoms on the RQLQ test after 3 weeks of treatment during ragweed season compared to the placebo (p=0.017)
Reduction of allergy symptoms on the RQLQ test after 3 weeks of treatment during ragweed season compared to the placebo (p=0.017)

Individual symptoms (rhinorrhea, itching, and eye symptoms) were significantly reduced compared to the placebo.
Reduction in rhinorrhea on the SARS test after 3 weeks of treatment compared to the placebo (p=0.048)
Reduction in rhinorrhea on the SARS test after 3 weeks of treatment compared to the placebo (p=0.048)
Reduction in itching on SARS test after 3 weeks of treatment in ragweed season compared to placebo (p=0,041)
Reduction in itching on SARS test after 3 weeks of treatment in ragweed season compared to placebo (p=0,041)

Lectranal® was especially successful in the reduction of eye symptoms. Both the SARS and the Mini RQLQ showed a statistically significant reduction in eye symptoms.
Reduction in eye symptoms on the SARS test after 3 weeks of treatment during ragweed season compared to the placebo (p=0.048)
Reduction in eye symptoms on the SARS test after 3 weeks of treatment during ragweed season compared to the placebo (p=0.048)
Reduction in eye symptoms on the RQLQ after 3 weeks of treatment during ragweed season compared to the placebo (p=0.001)
Reduction in eye symptoms on the RQLQ after 3 weeks of treatment during ragweed season compared to the placebo (p=0.001)
  1   |   2   |   3  
RELATED ARTICLES
Preclinical toxicity study on Lectranal®
How does Lectranal® work
Lectranal® and intradermal inflammatory reactions
An assay for immunoglobulines in the blood of mice treated with Lectranal®
Lectranal®, inflammatory reaction, and gene expression in mouse spleen
Disclaimer | General Conditions Of Use | Privacy Statement | Imprint All rights reserved, Lectranal 2006
Design by: Studio2M       Powered by: CorvusCMS